Hopeful results from trials of dengue vaccine candidate
Phase 2 and 3 randomized, controlled clinical trials of Takeda's tetravalent (four-strain) dengue vaccine candidate show that it is safe, produces immunity in children, and protects against the disease — regardless of previous exposure to different strains of the virus, according to studies published in The Lancet. In the phase 3 double-blind trial, 20,099 children 4 to 16 years old at 26 centers in endemic areas of Asia and Latin America were randomly assigned to receive two doses of the live TAK-003 vaccine or two doses of placebo three months apart from September 2016 to August 2017.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063